CYP2D6 and major depressive disorder: The results of our study show that one in three patients with MDD treated with venlafaxine took a CYP2D6 substrate or inhibitor (23% venlafaxine-substrate and 10.3% venlafaxine-inhibitor), similar to the 27% found in the study by Preskorn [11].